FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to treating diseases related to insulin resistance. A method of treating involves administering an effective amount of IL-17A and/or IL-17F antagonist, wherein the above agonist represents an antibody or its antigen-binding fragment. The group of inventions also refers to a pharmaceutical composition containing the IL-17A and/or IL-17F antagonist with a pharmaceutically acceptable additive added, and to a set containing the above agonist, and an administration instruction.
EFFECT: using the given group of inventions enables reducing the insulin resistance in an individual by administering pro-inflammatory factors IL-17A and/or IL-17F antagonists.
20 cl, 3 ex, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-17F ANTIBODIES AND METHODS FOR USE THEREOF | 2010 |
|
RU2605318C2 |
| HETERODIMERIC POLIPEPTIDES IL-17 A/F AND POSSIBILITIES OF THEIR THERAPEUTIC APPLICATION | 2007 |
|
RU2440134C2 |
| TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
| ANGIOPOIETIC ANGIOPOIETIN-LIKE PROTEIN 4 INHIBITORS, IN COMBINATIONS AND APPLICATION | 2005 |
|
RU2392966C2 |
| APOPTOTIC ANTIBODIES AGAINST IgE | 2008 |
|
RU2500686C2 |
| DETECTION METHOD OF INTESTINE INFLAMMATORY DISEASE | 2008 |
|
RU2502806C2 |
| METHOD FOR INHIBITION OF HEPATOCYTE PROLIFERATION, METHOD FOR INHIBITION OF HEPATOCYTE CELL ADHESION AND METHOD FOR INHIBITION OF BIOLOGICAL ACTIVITY ANGPTL4 IN HEPATOCYTES OR HEPATOCYTE PRECURSORS | 2005 |
|
RU2380411C2 |
| COMBINED THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES BY USING COMBINATION OF ELIMINATING B-CELLS AND IMMUNOREGULATORY ANTIBODIES | 2001 |
|
RU2285541C2 |
| ANTIBODY-FYNOMER CONJUGATES | 2015 |
|
RU2732226C2 |
| METHODS FOR TREATMENT USING ANTI-IL-17A ANTIBODIES | 2016 |
|
RU2754683C2 |
